Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C

A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with hepatitis C virus gentoypes 1, 4, or 6, according to results of the C-EDGE trial presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. However, the study also showed that people with higher baseline HCV viral load and genotype 1a may have a poorer response to this combination, particularly if they have naturally occurring HCV variants that are less sensitive to drugs from the NS5A inhibitor class.

alt

Read more:

EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C virus infection in 12 weeks in some groups of treatment-experienced patients and in HIV/HCV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even for the hardest-to-treat groups of treatment-experienced patients, according to 2 studies presented last week at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.

alt

Read more:

EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals

Treatment for 12 weeks with grazoprevir and elbasvir, 2 direct-acting antivirals being development by Merck, plus ribavirin, cured 95% of people with hepatitis C who had experienced failure of a previous combination containing an HCV protease inhibitor, Xavier Forns of the University of Barcelona Hospital Clinic reported the at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.

alt

Read more:

EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients

A 12-week course of treatment with 2 direct-acting antivirals in development by Merck cured hepatitis C virus infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, Ira Jacobson of Weill Cornell Medical College reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna. The Phase 2 study looked at the use of the HCV protease inhibitor grazoprevir and the NS5A inhibitor elbasvir in people with Child-Pugh B cirrhosis.

alt

Read more:

Allergy Drug Inhibits Hepatitis C Virus Replication in Mouse Study

The over-the-counter allergy medication chlorcyclizine HCl, or CCZ, was found to be a potent inhibitor of hepatitis C virus (HCV) genotype 1b and 2a replication, according to a laboratory study described in the April 8 edition of Science Translational Medicine. The study authors suggest that this older drug could potentially be an affordable component of combination treatment. A Phase 1 clinical trial is now underway.

alt

Read more: